Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused By Diabetic Neuropathy Arcion Therapeutics, Inc., a venture backed clinical stage biotechnology company that develops pain therapies, announced the presentation of data demonstrating that its lead candidate, ARC-4558, significantly reduced pain caused by diabetic neuropathy in a double-blind, placebo-controlled trial. The abstract will be presented in a poster session on May 8th from 4:00-5:30 PM at the American Pain Society Annual Meeting, held May 7-9 in San Diego. ARC-4558 is a 0.
Source: www.medicalnewstoday.comBurzynski Research Institute Announces Positive Results Of Phase II ANP Clinical Trial The Burzynski Research Institute (BRI) announced positive safety and efficacy results in its Phase II clinical trial of Antineoplaston A10 and Antineoplaston AS2-1 therapy (ANP therapy) in children with optic pathway glioma (OPG). The results were presented to the
FDA in the Request for End of Phase II Meeting Briefing Package (ANP in OPG), to be discussed at a meeting with the
FDA on May 7, 2009.
Source: www.medicalnewstoday.comRAPAFLO(TM) (silodosin) Provides Rapid And Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief In As Little As Three Days RAPAFLO(TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produces rapid improvements of both irritative and obstructive urinary symptoms that were sustained for 12 weeks, according to data published in the June issue of The Journal of Urology. RAPAFLO(TM) was developed and is manufactured by Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals.
Source: www.medicalnewstoday.comCutaneous Application Of Nanoparticles Offers Hope For Treatment Of Erectile Dysfunction Cutaneous application of nanoparticles may offer a new means of delivering drugs to treat erectile dysfunction (ED), according to findings presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA). Topical treatments for ED may offer localized therapeutic results with the benefit of lower dosage and the avoidance of adverse side effects due to systemic absorption.
Source: www.medicalnewstoday.comNew Data Shows AZOR(R) (amlodipine And Olmesartan Medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure Daiichi Sankyo, Inc. announced that data presented at the American Society of Hypertension, Inc. (ASH) Twenty-Fourth Annual Scientific Meeting and Exposition (ASH 2009) in San Francisco from the AZOR(R) Trial Evaluating Blood Pressure Reductions and Control (AZTEC) demonstrated that a stepwise amlodipine and olmesartan medoxomil-based titration regimen provided mean 24-hour ambulatory reductions in systolic blood pressure (SBP) of 21.4 mm Hg and diastolic blood pressure (DBP) of 12.7 mm Hg.
Source: www.medicalnewstoday.comAmerican Society of Health-System Pharmacists Honors Members For Practice Excellence And Leadership Thirty-two health-system pharmacists have been given the title "Fellow" by the American Society of Health-System Pharmacists (ASHP) in recognition of the excellence they have achieved in
pharmacy practice. The 2009 Fellows will be honored on Tuesday, June 16, 2009, during the ASHP Summer Meeting in Rosemont, IL. The ASHP Practitioner Recognition Program recognizes excellence in practice and promotes public awareness of outstanding pharmacists.
Source: www.medicalnewstoday.com
# posted by Network @ 12:15 AM
